Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
China Resources Pharmaceutical Group Limited has announced that its wholly owned subsidiary China Resources Pharmaceutical Holdings Company Limited has completed the public issuance of the first tranche of its 2026 corporate bonds in mainland China. The bonds, approved by the China Securities Regulatory Commission for a larger programme of up to RMB10 billion, were issued in an initial principal amount of RMB1.5 billion.
The three-year bonds carry an annual coupon rate of 1.65%, and the net proceeds will be directed toward production-related expenditures, including debt repayment, working capital replenishment, project development and operations, and investments in scientific and technological innovation. The financing is expected to strengthen the group’s capital structure, support ongoing expansion of its pharmaceutical operations in the PRC and potentially enhance its long-term competitiveness and funding flexibility for stakeholders.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated company operating in the pharmaceutical industry, primarily through its wholly owned subsidiary China Resources Pharmaceutical Holdings Company Limited. The group focuses on manufacturing, distribution and related healthcare services in mainland China, targeting qualified institutional investors and broader healthcare demand in the PRC market.
Average Trading Volume: 17,889,461
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$39.96B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.